Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial


Malmstrom A., Gronberg B. H. , Marosi C., Stupp R., Frappaz D., Schultz H., ...Daha Fazla

LANCET ONCOLOGY, cilt.13, ss.916-926, 2012 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 13 Konu: 9
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/s1470-2045(12)70265-6
  • Dergi Adı: LANCET ONCOLOGY
  • Sayfa Sayıları: ss.916-926

Özet

Background Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years. We did a randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma.